NCT00002073View on ClinicalTrials.gov

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

NACompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
HIV InfectionsCytopenias
Interventions
DRUG

Epoetin alfa

Trial Locations (1)

088690602

Ortho Pharmaceutical Corp, Raritan

Sponsors
All Listed Sponsors
lead

Ortho Pharmaceuticals

INDUSTRY

NCT00002073 - A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy | Biotech Hunter | Biotech Hunter